Bahija Jallal joins from AstraZeneca where she was President and head of its global biologics research and development unit, MedImmune. She was a member of the senior executive team at AstraZeneca reporting to the CEO.  During her time at MedImmune, she oversaw significant growth in the AstraZeneca biologics pipeline across a range of disease areas.

“Bahija Jallal’s appointment as CEO of Immunocore strengthens the company’s  management team and signals that it is entering a period of significant clinical and commercial maturity,” said Jean-Michel Cossery, Non-Executive Director of Malin and Malin’s Immunocore Board designate.

Malin owns approximately 10% of Immunocore and carried its investment in Immunocore at €85.1 million at 30 June 2018 in its portfolio fair value estimateunder International Private Equity Valuation guidelines.